← Back

Precipio Inc

Precipio, Inc. is a healthcare biotechnology company that provides cancer diagnostic products, reagents, and services in the United States. It offers diagnostic blood cancer testing services, including HemeScreen, a suite of genetic diagnostic panels, and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. The company also provides biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

Price · split & dividend adjusted
News & notes moving PRPO
PRPO

Precipio reports Q2 revenue of $7M, up 22.8%

Precipio announced its Q2 2026 financial results, with revenue of $7 million, a 22.8% increase year-over-year. Adjusted EBITDA was $0.4 million, compared to a loss of $0.2 million in Q1 2026. Cash flow from operations was $0.7 million, and total cash increased by $0.5 million, bringing the quarter-end cash balance to over $3 million, up from $1.1 million in Q2 2025.
Seeking Alpha·32dRead more →